NovoLog® (insulin aspart [rDNA origin] injection) is different from regular human insulin. It works faster and will not work as long as regular human insulin. A NovoLog® injection should immediately be followed by a meal. Because of the short duration of action of NovoLog®, patients also require a longer-acting insulin to maintain adequate glucose control. Low blood glucose is the most common side effect of insulin therapy, including NovoLog®. Any change in insulin should be made cautiously and only under medical supervision. Do not use NovoLog® if your blood sugar is too low or if you are allergic to insulin aspart or any of the ingredients contained in NovoLog®.

Pump or infusion set malfunctions or insulin quality can result in inadequate insulin infusion and can lead to hyperglycemia and ketosis. These problems can quickly occur due to the faster absorption and shorter duration of action of NovoLog compared to buffered regular insulin. It is important to quickly identify the cause of and correct these problems. Glucose monitoring is recommended for all patients with diabetes, particularly those using external pump infusion therapy.

Indications and Usage: NovoLog® is for use in patients with diabetes to control high blood glucose.

FlexPen and NovoLog are registered trademarks of Novo Nordisk A/S.
© 2006 Novo Nordisk Inc.   All rights reserved.     September 2006

Disclaimer | Privacy | Contact Us | Novonordisk-us.com

 If you do not have Adobe^® Reader^® you can get it here.